Nav: Home

Houston Methodist receives $9 million from NCI to study physics of cancer immunotherapy

October 04, 2016

HOUSTON-(Oct. 3, 2016)-The Houston Methodist Research Institute has been awarded a $9 million grant from the National Cancer Institute to establish a research center focused on the physics of cancer immunotherapy.

The Houston Methodist Research Institute will be the lead site for the NCI-designated Center for Immunotherapeutic Transport Oncophysics (CITO), which focuses on designing immunotherapies for breast and pancreatic cancers. While several immunotherapies have been approved by the U.S. Food and Drug Administration, the use of immunotherapy to treat these intractable cancers has been less effective.

Houston Methodist is partnering with the University of Texas M.D. Anderson Cancer Center and UT Southwestern to receive the NCI grant to explore physiological changes during cancer progression. Studying the body's changes, rather than simply focusing on the tumor, will help researchers create more effective and personalized treatments with fewer side effects.

Through a multidisciplinary and multi-institutional research team led by Mauro Ferrari, Ph.D., president and CEO of the Houston Methodist Research Institute, the CITO will combine the studies of cancer immunology, biotechnology and transport oncophysics (mass transport within cancer cells) to reveal how immunotherapy works in cancer patients.

Ferrari, considered a pioneer of transport oncophysics explained, "Many cancer patients do not respond to immunotherapies, typically because the drugs never reach the cancer cells. While transport oncophysics is a relatively young field of study, we need to understand the limitations of treatments to identify effective immunotherapies for patients."

The center's goal is to use research information to personalize immunotherapies for the treatment of breast and pancreatic cancers: topics of the two major center projects.

The first project will determine how nano-dendritic cell vaccines, containing immune cells loaded with nanoparticles, are transported to breast cancers. The second project aims to identify the transport barriers keeping immunotherapies from reaching pancreatic tumors.

Houston Methodist is one of 10 institutions receiving an NCI center grant. Others include Cornell University, Dana-Faber Cancer Institute, Johns Hopkins University and Massachusetts Institute of Technology (MIT).
-end-
To speak with Mauro Ferrari, Ph.D., contact Patricia Akinfenwa, Houston Methodist, at 281.740.1402 or pakinfenwa@houstonmethodist.org. For more information about Houston Methodist, visit houstonmethodist.org. Follow us on Twitter and Facebook.

Houston Methodist

Related Cancer Cells Articles:

Cancer cells send signals boosting survival and drug resistance in other cancer cells
Researchers at University of California San Diego School of Medicine report that cancer cells appear to communicate to other cancer cells, activating an internal mechanism that boosts resistance to common chemotherapies and promotes tumor survival.
A protein that stem cells require could be a target in killing breast cancer cells
Researchers have identified a protein that must be present in order for mammary stem cells to perform their normal functions.
Single gene encourages growth of intestinal stem cells, supporting 'niche' cells -- and cancer
A gene previously identified as critical for tumor growth in many human cancers also maintains intestinal stem cells and encourages the growth of cells that support them, according to results of a study led by Johns Hopkins researchers.
Prostate cancer cells grow with malfunction of cholesterol control in cells
Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem.
Immune therapy scientists discover distinct cells that block cancer-fighting immune cells
Princess Margaret Cancer Centre scientists have discovered a distinct cell population in tumours that inhibits the body's immune response to fight cancer.
New system developed that can switch on immune cells to attack cancer cells
Researchers have developed an artificial structure that mimics the cell membrane, which can switch on immune cells to attack and destroy a designated target.
Hybrid immune cells in early-stage lung cancer spur anti-tumor T cells to action
Researchers have identified a unique subset of these cells that exhibit hybrid characteristics of two immune cell types -- neutrophils and antigen-presenting cells -- in samples from early-stage human lung cancers.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Sleep hormone helps breast cancer drug kill more cancer cells
Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects.
Breast cancer tumor-initiating cells use mTOR signaling to recruit suppressor cells to promote tumor
Baylor College of Medicine researchers report a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.

Related Cancer Cells Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...